title: Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
abstract: Virus-like particles (VLPs) of bacteriophage MS2 possess numerous features that make them well-suited for use in targeted delivery of therapeutic and imaging agents. MS2 VLPs can be rapidly produced in large quantities using in vivo or in vitro synthesis techniques. Their capsids can be modified in precise locations via genetic insertion or chemical conjugation, facilitating the multivalent display of targeting ligands. MS2 VLPs also self-assemble in the presence of nucleic acids to specifically encapsidate siRNA and RNA-modified cargos. Here we report the use of MS2 VLPs to selectively deliver nanoparticles, chemotherapeutic drugs, siRNA cocktails, and protein toxins to human hepatocellular carcinoma (HCC). MS2 VLPs modified with a peptide (SP94) that binds HCC exhibit a 10(4)-fold higher avidity for HCC than for hepatocytes, endothelial cells, monocytes, or lymphocytes and can deliver high concentrations of encapsidated cargo to the cytosol of HCC cells. SP94-targeted VLPs loaded with doxorubicin, cisplatin, and 5-fluorouracil selectively kill the HCC cell line, Hep3B, at drug concentrations <1 nM, while SP94-targeted VLPs that encapsidate a siRNA cocktail, which silences expression of cyclin family members, induce growth arrest and apoptosis of Hep3B at siRNA concentrations <150 pM. Impressively, MS2 VLPs, when loaded with ricin toxin A-chain (RTA) and modified to codisplay the SP94 targeting peptide and a histidine-rich fusogenic peptide (H5WYG) that promotes endosomal escape, kill virtually the entire population of Hep3B cells at an RTA concentration of 100 fM without affecting the viability of control cells. Our results demonstrate that MS2 VLPs, because of their tolerance of multivalent peptide display and their ability to specifically encapsidate a variety of chemically disparate cargos, induce selective cytotoxicity of cancer in vitro and represent a significant improvement in the characteristics of VLP-based delivery systems.
authors: Center for Micro-Engineered Materials, University of New Mexico, Albuquerque, New Mexico 87131, USA. ceashle@sandia.gov
authors: Carlee E
authors: CE
authors: Ashley
authors: Eric C
authors: EC
authors: Carnes
authors: Genevieve K
authors: GK
authors: Phillips
authors: Paul N
authors: PN
authors: Durfee
authors: Mekensey D
authors: MD
authors: Buley
authors: Christopher A
authors: CA
authors: Lino
authors: David P
authors: DP
authors: Padilla
authors: Brandy
authors: B
authors: Phillips
authors: Mark B
authors: MB
authors: Carter
authors: Cheryl L
authors: CL
authors: Willman
authors: C Jeffrey
authors: CJ
authors: Brinker
authors: Jerri do Carmo
authors: Jdo C
authors: Caldeira
authors: Bryce
authors: B
authors: Chackerian
authors: Walker
authors: W
authors: Wharton
authors: David S
authors: DS
authors: Peabody
references: Hepatology. 2003 Mar;37(3):534-43
references: 12601350
references: Neurol Res. 2006 Jul;28(5):493-9
references: 16808878
references: Ann Oncol. 2009 Aug;20(8):1402-7
references: 19502532
references: J Mol Biol. 2011 Jun 3;409(2):225-37
references: 21501621
references: Adv Drug Deliv Rev. 2006 Dec 1;58(14):1505-22
references: 17118484
references: Clin Cancer Res. 1996 Mar;2(3):531-9
references: 9816200
references: J Control Release. 1999 May 20;59(2):133-48
references: 10332049
references: Nat Med. 2006 Mar;12(3):354-60
references: 16501571
references: J Nanobiotechnology. 2007 Nov 26;5:10
references: 18039380
references: Nano Lett. 2007 Aug;7(8):2207-10
references: 17630809
references: Cancer Res. 2003 Jul 1;63(13):3593-7
references: 12839946
references: Clin Cancer Res. 2000 May;6(5):1949-57
references: 10815920
references: Chem Biol. 2007 Oct;14(10):1152-62
references: 17961827
references: Nat Nanotechnol. 2007 Dec;2(12):751-60
references: 18654426
references: Oncogene. 2006 Mar 16;25(12):1753-62
references: 16278675
references: Nanomedicine. 2005 Mar;1(1):67-76
references: 17292060
references: Nat Nanotechnol. 2008 Mar;3(3):131-2
references: 18654480
references: Angew Chem Int Ed Engl. 2009;48(50):9493-7
references: 19921725
references: J Nanobiotechnology. 2006 Feb 13;4:2
references: 16476163
references: J Am Chem Soc. 2009 Aug 12;131(31):11174-8
references: 19603808
references: Nat Nanotechnol. 2008 Mar;3(3):145-50
references: 18654486
references: Adv Drug Deliv Rev. 2009 Sep 30;61(11):931-9
references: 19596034
references: Nat Rev Cancer. 2002 Jan;2(1):48-58
references: 11902585
references: Chem Commun (Camb). 2008 Mar 14;(10):1205-7
references: 18309418
references: Chem Biol. 2007 Jan;14(1):107-15
references: 17254956
references: Bioconjug Chem. 2007 Jul-Aug;18(4):1140-7
references: 17602681
references: Bioconjug Chem. 1995 Sep-Oct;6(5):587-95
references: 8974458
references: J Biol Chem. 2004 Apr 30;279(18):19264-75
references: 14960581
references: PLoS Pathog. 2009 May;5(5):e1000417
references: 19412526
references: Nat Biotechnol. 2005 Nov;23(11):1418-23
references: 16244656
references: J Biol Chem. 2006 Feb 10;281(6):3544-51
references: 16326716
references: Biotechnol Bioeng. 2008 May 1;100(1):28-37
references: 18023052
references: Nucleic Acids Res. 1993 Sep 25;21(19):4621-6
references: 8233800
references: J Gene Med. 2008 Oct;10(10):1134-49
references: 18642401
references: Bioorg Med Chem. 2006 Nov 1;14(21):7138-45
references: 16875827
references: Mol Cancer Ther. 2008 Mar;7(3):579-89
references: 18347144
references: Nat Struct Biol. 1998 Mar;5(3):174-6
references: 9501905
references: J Am Chem Soc. 2004 Mar 31;126(12):3718-9
references: 15038717
references: J Mol Biol. 2008 Jun 27;380(1):252-63
references: 18508079